RecruitingPhase 2NCT03949855
Belimumab With Rituximab for Primary Membranous Nephropathy
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Patrick NachmanUniversity of Minnesota, Department of Medicine, Division of Renal Diseases and Hypertension
- Intervention
- Belimumab(drug)
- Enrollment
- 58 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2020 – 2030
Study locations (20)
- University of Alabama at Birmingham School of Medicine: Division of Nephrology, Birmingham, Alabama, United States
- University of Arkansas, Little Rock, Arkansas, United States
- University of California San Francisco, San Francisco, California, United States
- Stanford University School of Medicine: Division of Nephrology, Stanford, California, United States
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension, Torrance, California, United States
- University of Colorado, Aurora, Colorado, United States
- Mayo Clinic Jacksonville: Department of Nephrology and Hypertension, Jacksonville, Florida, United States
- University of Miami Miller School of Medicine, Div of Nephrology, Miami, Florida, United States
- Johns Hopkins, Baltimore, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota Health Clinical Research Unit, Minneapolis, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Nebraska, Omaha, Nebraska, United States
- Columbia University Medical Center: Division of Nephrology, New York, New York, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Immune Tolerance Network (ITN) · GlaxoSmithKline · PPD Development, LP · Rho Federal Systems Division, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03949855 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.